CAMP4 Therapeutics Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of regulatory RNA-based therapeutics with the goal of upregulating gene expression and restoring healthy protein levels to treat a range of genetic diseases. It is leveraging its RAP Platform to advance a pipeline of programs focused on metabolic and central nervous system (CNS) disorders with validated disease biology and potential market opportunities due to the significant unmet need of affected patients. Its lead product candidate, CMP-CPS-001, has the potential to be the first disease-modifying therapy for the treatment of urea cycle disorders. CMP-CPS-001 is designed to improve urea cycle activity by amplifying expression of CPS1, a key enzyme that catalyzes the first step of the urea cycle, by binding to a CPS1-specific regRNA. Its CNS development program, CMP-SYNGAP, is focused on addressing the underlying cause of SYNGAP1-related disorders.
Alto Crescimento
A receita da empresa tem crescido de forma consistente nos últimos 3 anos, com média de 899.43% ano a ano.
Em Crescimento
A empresa está em fase de crescimento, com a receita anual mais recente totalizando US$ 3.50M.
Alto Crescimento de Lucro
O lucro líquido da empresa lidera o setor, com o lucro anual mais recente totalizando US$ 3.50M.
Avaliação Justa
O PE mais recente da empresa é -1.89, em uma faixa percentil média de 3 anos.
Compra Institucional
As participações institucionais mais recentes são de 42.58M ações, um aumento de 25.65% em relação ao trimestre anterior.
Mantido por Steven Cohen
O Super Investidor Steven Cohen possui 18.15K ações desta empresa.